Published in J Clin Pathol on September 01, 2000
Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol (2002) 2.48
Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients. Int J Oncol (2012) 0.87
My approach to intraductal lesions of the prostate gland. J Clin Pathol (2007) 0.82
The frequency of latent prostate carcinoma in autopsies of over 50 years old males, the Iranian experience. Med J Islam Repub Iran (2012) 0.81
Prostate field cancerization: deregulated expression of macrophage inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A (PDGF-A) in tumor adjacent tissue. PLoS One (2015) 0.81
Chemopreventive trials in urologic cancer. Rev Urol (2006) 0.78
Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate. Eur Radiol (2016) 0.77
Strategies for prostate cancer prevention: Review of the literature. Indian J Urol (2008) 0.77
Quantitative immunohistochemical detection of the molecular expression patterns in proliferative inflammatory atrophy. J Mol Histol (2006) 0.77
High grade prostatic intraepithelial neoplasia with squamous differentiation. J Clin Pathol (2006) 0.75
Association and regulation of protein factors of field effect in prostate tissues. Int J Oncol (2016) 0.75
Electronic publishing and internet learning. J Clin Pathol (2002) 0.75
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer (1993) 2.56
Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol (1986) 2.01
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression. Cancer Cells (1991) 1.95
Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85
Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer (1987) 1.79
Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev (1999) 1.76
Latent Carcinoma of the Prostate. J Clin Pathol (1949) 1.72
Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer (1991) 1.61
Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res (1995) 1.52
Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol (1996) 1.46
DNA in human tumors: a cytophotometric study. Curr Top Pathol (1975) 1.41
The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer (1991) 1.39
Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol (1985) 1.36
Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol (1995) 1.33
Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res (1996) 1.28
Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol (1996) 1.27
Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res (1994) 1.24
Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol (1993) 1.23
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol (1994) 1.21
The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol (1997) 1.20
Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res (1994) 1.16
Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosomes Cancer (1994) 1.15
Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol (1996) 1.15
Pathological changes in prostate lesions after androgen manipulation. J Clin Pathol (1998) 1.13
The significance of prostatic intra-epithelial neoplasia. Br J Urol (1995) 1.09
Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol (1999) 1.08
Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications. Am J Surg Pathol (1998) 1.08
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol (1996) 1.08
Large acinar atypical hyperplasia and carcinoma of the prostate. Cancer (1988) 1.07
Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol (1997) 1.07
Ductal spread in prostatic carcinoma. Cancer (1985) 1.05
Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. Urology (1991) 1.02
Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. Hum Pathol (1998) 1.01
Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J Urol (1996) 0.99
Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate (1995) 0.98
Interobserver variability in the diagnosis of high-grade prostatic intraepithelial neoplasia and adenocarcinoma. Mod Pathol (1996) 0.96
Unusual histologic types of high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol (1997) 0.96
Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol (1993) 0.95
Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. Genes Chromosomes Cancer (1995) 0.94
Analysis of cribriform morphology in prostatic neoplasia using antibody to high-molecular-weight cytokeratins. Arch Pathol Lab Med (1994) 0.94
Cribriform adenocarcinoma of the prostate. Cancer (1986) 0.92
Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol (1994) 0.92
Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents. J Clin Pathol (1999) 0.91
Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology (1994) 0.90
Microcarcinoma in the prostate: its association with duct-acinar dysplasia. Hum Pathol (1991) 0.89
Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate (1998) 0.89
Expression of glutathione-S-transferase-pi in human tumours. Eur J Cancer (1992) 0.89
Use of transrectal ultrasound and prostate-specific antigen in diagnosis of prostatic intraepithelial neoplasia. Urology (1989) 0.89
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol (1995) 0.88
Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer? Br J Urol (1997) 0.87
Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol (1995) 0.87
Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res (1995) 0.87
Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA). Pathol Res Pract (1993) 0.85
Foamy gland high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol (2000) 0.85
Expression of pi-class glutathione S-transferase: two populations of high grade prostatic intraepithelial neoplasia with different relations to carcinoma. Mol Pathol (2000) 0.84
Neuroendocrine differentiation in prostatic adenocarcinoma does not represent true Paneth cell differentiation. Hum Pathol (1994) 0.84
Minimal criteria for the diagnosis of prostate cancer on needle biopsy. Ann Diagn Pathol (1997) 0.84
Is prostatic intraepithelial neoplasia in the transition/central zone a true precursor of cancer? A long-term retrospective study in Norway. Br J Cancer (1998) 0.84
Pre-neoplastic lesions of the prostate. Histopathology (1995) 0.82
Evaluation of prostatic intraepithelial neoplasia after treatment with a 5-alpha-reductase inhibitor (finasteride). A methodologic approach. Anal Quant Cytol Histol (1996) 0.82
DNA distribution in the prostate. Normal gland, benign and premalignant lesions, and subsequent adenocarcinomas. Anal Quant Cytol Histol (1993) 0.82
Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens. Urology (1997) 0.82
Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol (1999) 0.82
Prostatic intraepithelial neoplasia: detection and correlation with invasive cancer in fine-needle biopsy. Urology (1989) 0.81
Prostatic intra-epithelial neoplasia. Qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. Pathol Res Pract (1993) 0.81
Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens. Urology (1997) 0.81
The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Pathol Res Pract (1995) 0.81
Subtle morphological and molecular changes in normal-looking epithelium in prostates with prostatic intraepithelial neoplasia or cancer. Eur Urol (1999) 0.81
Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas. Diagn Mol Pathol (1997) 0.80
Morphogenesis of prostatic carcinoma. Cancer (1965) 0.80
DNA methylation, molecular genetic, and linkage studies in prostate cancer. Prostate Suppl (1996) 0.80
Distribution pattern of basal cells detected by cytokeratin 34 beta E12 in primary prostatic duct adenocarcinoma. Am J Surg Pathol (1997) 0.80
Relationship of severe dysplasia to stage B adenocarcinoma of the prostate. Cancer (1990) 0.79
Relationship of severe dysplasia to stage A (incidental) adenocarcinoma of the prostate. Cancer (1990) 0.79
Chromatin texture in high grade prostatic intraepithelial neoplasia and early invasive carcinoma. Anal Quant Cytol Histol (1999) 0.78
Digital image analysis of proliferative index: two distinct populations of high-grade prostatic intraepithelial neoplasia in close proximity to adenocarcinoma of the prostate. Hum Pathol (1998) 0.78
An Address on Involutionary Changes in Prostate and Female Breast in Relation to Cancer Development. Can Med Assoc J (1926) 0.78
Potential markers of aggressiveness in prostatic intraepithelial neoplasia detected by fluorescence in situ hybridization. Eur Urol (1996) 0.76
Prostatic intraepithelial neoplasia and other changes during promotion and progression. Pathol Res Pract (1995) 0.76
Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia. Eur Urol (1996) 0.76
Neuroendocrine differentiation in the precursors of prostate cancer. Eur Urol (1996) 0.76
Significance of duct-acinar dysplasia in prostatic carcinogenesis. Prostate (1988) 0.76
Putative precursor lesions of prostatic adenocarcinoma: fact or fiction? Mod Pathol (1993) 0.76
Diagnostic limits in precursor lesions of prostatic cancer. Eur Urol (1996) 0.76
Re: Risk factors for perineal seeding of prostate cancer after needle biopsy. J Urol (1990) 0.76
Case diagnosis as positive identification in prostatic neoplasia. Anal Quant Cytol Histol (1998) 0.75
Working standards in prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Pathol Res Pract (1995) 0.75
Neuroendocrine cells in peripheral prostatic zone: age, prostatic intraepithelial neoplasia and latent cancer-related changes. Eur Urol (1995) 0.75
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.53
Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol (2000) 2.38
TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997) 1.80
Prostatic adenocarcinoma with glomeruloid features. Hum Pathol (1998) 1.63
Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation. J Pathol (2007) 1.50
Metastatic tumor of the epididymis and spermatic cord. Eur Urol (1983) 1.50
OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol (2007) 1.44
[Squamous cell carcinoma of the penis: treatment protocol according to our 14 years of experience]. Arch Esp Urol (1997) 1.37
Malignant myoepithelioma of the salivary glands: clinicopathological and immunohistochemical features. Br J Oral Maxillofac Surg (1999) 1.31
Molecular biology of prostatic intraepithelial neoplasia. Prostate (1996) 1.22
Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology (1993) 1.20
Pseudoneoplastic lesions of the testis and paratesticular structures. Virchows Arch (2007) 1.19
EAU Guidelines on Penile Cancer. Eur Urol (2004) 1.19
[EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. Actas Urol Esp (2011) 1.19
Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. Urology (1997) 1.16
Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther (2000) 1.16
Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol (2001) 1.11
Grade, local stage and growth pattern as prognostic factors in carcinoma of the penis. Eur Urol (1997) 1.06
The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol (2007) 1.03
Assessment of prostate carcinoma in core needle biopsy--definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer (1996) 0.99
Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol (2002) 0.95
Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J Urol (2005) 0.94
Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int J Immunopathol Pharmacol (2009) 0.93
Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol (2006) 0.93
Balanitis xerotica obliterans in children. J Urol (1986) 0.92
Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol (2007) 0.91
Morphometric index of adult renal cell carcinoma. Comparison with the Fuhrman grading system. Virchows Arch (2000) 0.91
Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents. J Clin Pathol (1999) 0.91
Growing teratoma syndrome: experience of a single institution. Eur Urol (1997) 0.90
Downregulation of Fc gamma receptor IIIA alpha (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C. Cell Immunol (1994) 0.88
Morphological classification and definition of benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. Histopathology (2008) 0.88
Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression. J Clin Pathol (2005) 0.88
Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. Virchows Arch (2014) 0.87
Neonatal exposure of male rats to estradiol benzoate causes rete testis dilation and backflow impairment of spermatogenesis. Anat Rec (1998) 0.87
Morphological diagnosis of urothelial neoplasms. J Clin Pathol (2007) 0.86
Testicular pseudolymphoma. Eur Urol (1986) 0.85
Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential. Int J Immunopathol Pharmacol (2008) 0.85
Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase. Int J Immunopathol Pharmacol (2012) 0.85
Matrix Metalloproteinases and Bladder Cancer: What is New? ISRN Urol (2012) 0.85
Expression of pi-class glutathione S-transferase: two populations of high grade prostatic intraepithelial neoplasia with different relations to carcinoma. Mol Pathol (2000) 0.84
Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense gamma-enolase expression. Histopathology (1999) 0.84
Significance of ureteral carcinoma in situ in specimens of cystectomy. Eur Urol (1994) 0.83
Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J Clin Pathol (2003) 0.83
Handling and reporting of radical prostatectomy specimens in Europe: a web-based survey by the European Network of Uropathology (ENUP). Histopathology (2008) 0.83
Hepatocarcinoma and oral contraceptives. Lancet (1978) 0.82
Precancerous lesions in the kidney. Scand J Urol Nephrol Suppl (2000) 0.81
Ultrastructure of prostatic intraepithelial neoplasia. Prostate (1997) 0.81
Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate. Am J Surg Pathol (1994) 0.81
Treatment of transitional cell carcinoma of the ureter: is the controversy justified? Eur Urol (1990) 0.81
Clear cell adenocarcinoma in a female urethral diverticulum. Scand J Urol Nephrol (2000) 0.81
Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. Urology (2001) 0.81
Molecular staging of bladder cancer with RT-PCR assay for CK20 in peripheral blood, bone marrow and lymph nodes: comparison with standard histological staging. Anticancer Res (2006) 0.80
Nerve regeneration through a combined autologous conduit (vein plus acellular muscle grafts). Biomaterials (1998) 0.80
Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride. J Clin Pathol (1999) 0.80
Increased VEGF165 expression in HCT116 colon cancer cells after transient transfection with a GFP vector encoding HIF-1 gene. J Exp Clin Cancer Res (2007) 0.80
Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol (2002) 0.80
What is the added value of combined core biopsy and fine needle aspiration in the diagnostic process of renal tumours? World J Urol (2011) 0.80
Update on selected renal cell tumors with clear cell features. With emphasis on multilocular cystic clear cell renal cell carcinoma. Histol Histopathol (2013) 0.79
Assessment of radical prostatectomy specimens and diagnostic reporting of pathological findings. Pathologica (2001) 0.79
Intraepithelial lesions of urinary bladder: morphologic considerations. Scand J Urol Nephrol Suppl (2000) 0.79
Transitional cell carcinoma of the prostate. Eur Urol (1985) 0.79
Altered gene expression signature of early stages of the germ line supports the pre-meiotic origin of human spermatogenic failure. Andrology (2014) 0.79
Desmoplastic small round-cell tumor. Am J Surg Pathol (1992) 0.79
Nuclear changes in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer. Morphometric analysis in whole-mount sections. Virchows Arch (2000) 0.79
Prevalence of HIV-1 resistant strains in recent seroconverters. J Biol Regul Homeost Agents (2000) 0.79
Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy. Clin Nephrol (2008) 0.78
Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation. Int J Immunopathol Pharmacol (2010) 0.78
Gleason grading of prostate cancer. Contemporary approach. Pathologica (2005) 0.78
Septic arthritis due to streptococcus viridans. Clin Exp Rheumatol (1991) 0.78
Elevated E-cadherin and alpha/beta-catenin expression after androgen deprivation therapy in prostate adenocarcinoma. Pathol Res Pract (2003) 0.78
EAU guidelines on testicular cancer. Eur Urol (2001) 0.77
Reproducibility of histopathologic tumor grading in penile cancer--results of a European project. Virchows Arch (2014) 0.77
Immunohistochemical expression and localization of somatostatin receptors in normal prostate, high grade prostatic intraepithelial neoplasia and prostate cancer and its many faces. J Biol Regul Homeost Agents (2012) 0.77
Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis. Int J Immunopathol Pharmacol (2011) 0.77
Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol (1998) 0.77
Putative tissue markers in prostate cancer*. Urologia (2010) 0.77
Altered expression of the tetraspanin CD81 on B and T lymphocytes during HIV-1 infection. Clin Exp Immunol (2007) 0.77
Distinguishing cortical adrenal gland adenomas from carcinomas by their quantitative nuclear features. Anal Quant Cytol Histol (1999) 0.76
[Cystitis glandularis]. Arch Esp Urol (1999) 0.76
Changes in the normal-looking epithelium in prostates with PIN or cancer. Adv Clin Path (1999) 0.76
Origin of high-grade superficial bladder cancer. Eur Urol (1987) 0.76
Histological evaluation of superficial bladder tumors treated by Nd-YAG laser and transurethral resection. Eur Urol (1991) 0.76
Fibrous polyp of the ureter. Eur Urol (1981) 0.76
Meconium vaginalitis. Br J Urol (1991) 0.76
Large cell calcifying Sertoli cell tumour of the testis. Histopathology (1995) 0.76